Cantor Fitzgerald Comments on Rezolute FY2026 Earnings

Key Points

• Cantor Fitzgerald has projected that Rezolute, Inc. will report earnings of ($0.90) per share for FY2026, slightly better than the consensus estimate of ($0.93) per share.
• Despite missing a recent EPS estimate, Rezolute has received mixed ratings from analysts, with one "strong buy," six "buy," and one "sell," and an average target price of $11.83.
• Director Young-Jin Kim recently purchased over 1.23 million shares of Rezolute stock, increasing their ownership by 17.11% at an average price of $3.25 per share.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Rezolute in a research note issued on Thursday, July 24th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn ($0.90) per share for the year. The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05).

A number of other research analysts have also issued reports on the stock. Wedbush restated an "outperform" rating and issued a $12.00 target price on shares of Rezolute in a report on Wednesday, May 14th. Wall Street Zen lowered shares of Rezolute from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $14.00 price target on shares of Rezolute in a report on Monday, April 28th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $11.83.

Rezolute Stock Down 0.2%

RZLT opened at $5.87 on Friday. The firm has a market cap of $510.69 million, a P/E ratio of -5.10 and a beta of 1.03. The business's fifty day simple moving average is $4.53 and its 200 day simple moving average is $4.14. Rezolute has a 52 week low of $2.21 and a 52 week high of $6.21.

Institutional Trading of Rezolute

A number of hedge funds and other institutional investors have recently modified their holdings of RZLT. American Century Companies Inc. grew its stake in Rezolute by 5.2% during the 1st quarter. American Century Companies Inc. now owns 67,925 shares of the company's stock valued at $197,000 after purchasing an additional 3,334 shares in the last quarter. Pale Fire Capital SE raised its holdings in Rezolute by 9.1% in the first quarter. Pale Fire Capital SE now owns 47,122 shares of the company's stock valued at $137,000 after acquiring an additional 3,935 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in Rezolute by 48.5% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock valued at $97,000 after acquiring an additional 6,470 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after acquiring an additional 9,000 shares in the last quarter. Finally, Alpine Global Management LLC bought a new stake in shares of Rezolute in the 4th quarter worth about $54,000. 82.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Rezolute

In other news, Director Young-Jin Kim purchased 1,230,769 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were purchased at an average price of $3.25 per share, with a total value of $3,999,999.25. Following the purchase, the director directly owned 8,423,386 shares of the company's stock, valued at approximately $27,376,004.50. This represents a 17.11% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have acquired 1,241,345 shares of company stock valued at $4,041,196 in the last ninety days. 18.39% of the stock is currently owned by corporate insiders.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.